MSLE

Satellos Bioscience Inc

8.81

Sep 28 • 3:59 PM ET +0.11 (1.26%)

8.79

Aftermarket • 5:15 PM ET -0.02 (-0.24%)

Healthcare Biotechnology Canada Micro NASD

Sep 24, 7:35 AMSatellos Bioscience gets FDA clearance of IND for forazapadin in facioscapulohumeral muscular dystrophy

Peers: ANTX TNYA BDTX MOLN HURA MENS OKUR ORMP PLX SPRB

Scroll to Statements

Index	-
Market Cap	186.95M
Enterprise Value	125.11M
Income	-34.61M
Sales	0.00M
Book/sh	2.87
Cash/sh	2.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	18
IPO	Feb 19, 2009

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.06
P/C	3.02
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.22
Current Ratio	11.22
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.98
EPS next Y	-2.31
EPS next Q	-0.59
EPS this Y	-36.22%
EPS next Y	0.30%
EPS next 5Y	-9.33%
EPS past 3/5Y	16.48% 36.03%
Sales past 3/5Y	- -
EPS Y/Y TTM	-6.71%
Sales Y/Y TTM	-
EPS Q/Q	-43.13%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-8.53% -

Insider Own	27.85%
Insider Trans	0.00%
Inst Own	28.77%
Inst Trans	-0.01%
ROA	-64.76%
ROE	-70.45%
ROIC	-57.77%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.58%
SMA50	-7.19%
SMA200	5.21%
Trades

Shs Outstand	20.84M
Shs Float	15.31M
Short Float	0.54%
Short Ratio	1.57
Short Interest	0.08M
52W High	13.39 -34.23%
52W Low	5.30 66.14%
Volatility	4.88% 5.58%
ATR (14)	0.51
RSI (14)	43.67
Beta	1.51
Rel Volume	0.92
Avg Volume	52.36K
Volume	48,092

Perf Week	-4.03%
Perf Month	-8.32%
Perf Quarter	11.66%
Perf Half Y	42.33%
Perf YTD	49.83%
Perf Year	49.83%
Perf 3Y	115.93%
Perf 5Y	-37.57%
Perf 10Y	-12.60%
Recom	1.00
Target Price	21.81
Prev Close	8.70
Price	8.81
Change %	1.26%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-26	Initiated	Guggenheim	Buy	$23
Apr-06-26	Initiated	Leerink Partners	Outperform	$20
Mar-11-26	Initiated	Cantor Fitzgerald	Overweight

Sep-24-26 09:59AM	Satellos Receives FDA Clearance to Study Forazapadin in FSHD (InvestorsHub)
09:54AM	Satellos stock jumps after FDA clears FSHD trial for forazapadin (Investing.com)
07:00AM	Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development (GlobeNewswire)
Sep-15-26 07:00AM	Satellos to Present at the 31st Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-09-26 07:00AM	Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 (GlobeNewswire) +9.15%
07:00AM	Loading…
Sep-01-26 07:00AM	Satellos to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 05:16PM	Satellos Bioscience: Q2 Earnings Snapshot (Associated Press)
05:02PM	Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress (GlobeNewswire)
Jul-08-26 06:30AM	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 (GlobeNewswire) +9.38%
Jun-29-26 07:00AM	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +11.44%
Jun-25-26 07:00AM	Satellos to Present Clinical Program Updates at ICNMD 2026 (GlobeNewswire) +19.40%
Jun-17-26 05:00PM	Satellos Bioscience Announces Results of Annual Meeting of Shareholders (GlobeNewswire)
May-27-26 07:00AM	Satellos to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.98%
May-15-26 07:07AM	Satellos Bioscience: Q1 Earnings Snapshot (Associated Press)
07:00AM	Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress (GlobeNewswire)
07:00AM	Loading…
Apr-09-26 07:00AM	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Mar-27-26 09:15AM	Satellos Bioscience: Q4 Earnings Snapshot (Associated Press Finance) -10.68%
07:00AM	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-10-26 07:00AM	Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire) -18.11%
Feb-24-26 07:00AM	Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Feb-18-26 07:00AM	Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy (Business Wire)
Feb-17-26 07:00AM	Satellos to Participate in Upcoming Investor Conferences (Business Wire)
Feb-11-26 08:12AM	Satellos price target raised to $40 from $5 at Oppenheimer (TipRanks) +7.08%
Feb-10-26 07:00AM	Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (Business Wire)
Feb-09-26 05:00PM	Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Feb-06-26 08:30AM	Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States (Business Wire) -5.54%

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX and Leveraging MyoReGenX, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Co-FounderMr. Francis Gleeson B.B.A. M.B.A

CPAMs. Elizabeth Williams C.A.

Ph.D.Dr. Philip Lambert M.A.

M.P.H.Dr. Wildon Farwell M.D.

Co-Founder & Chief Discovery OfficerDr. Michael A. Rudnicki Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MSLE

Satellos Bioscience Inc

Upgrade your Finviz experience